Texas Peptides Inc. is one of six businesses Eli Lilly sued on August 12, 2026 over retatrutide. Here is what the complaint actually says, where the case stands, and what it means if you have ordered from them.
Lilly filed suit in the U.S. District Court for the Western District of Texas on August 12, 2026, case number 5:26-cv-05146, assigned to Judge Jason K. Pulliam. It is one of six actions filed the same day, four of them against research-use-only peptide sellers. Lilly is represented by Kirkland & Ellis and has demanded a jury.
The core allegation across all four peptide-seller cases is the same: that the “research use only” label was a pretext. Lilly alleges the defendants supplied dosing instructions, sold through consumer-facing storefronts without a prescription, and knowingly served buyers who intended to inject the compound themselves.
The legal framing is what makes these cases unusual. Lilly brought no patent claims and no trademark claims. It pleaded state consumer-protection statutes — Alaska, Colorado, Connecticut, North Carolina, South Carolina, Tennessee and Washington, plus Texas common law. The theory treats the RUO disclaimer not as a defence but as the misrepresentation itself. Lilly is seeking an injunction, disgorgement of profits, and attorney’s fees.
CBS News reported that Texas Peptides took down the web pages advertising retatrutide after the suit was filed. The company did not respond to press inquiries and has not filed a public denial.
Being named a defendant is not a finding of wrongdoing, and nothing in the complaint alleges that customers did anything unlawful. The practical concerns are commercial rather than legal: during active litigation, storefronts and product lines can disappear without notice, order fulfilment and support can be disrupted, and payment processors can withdraw — Lilly has publicly asked processors and platforms to do exactly that.
If you are looking at where to go next, the lesson from these filings is worth carrying with you. None of the six defendants was sued over product quality. They were sued over how the product was marketed. The vendors worth your trust are the ones that publish genuine third-party testing, keep their research-use framing honest, and don’t coach buyers on dosing themselves.
Two places to start: our side-by-side vendor comparison, and the vendors that publish a real COA library. Our guide to reading a COA shows you how to check the paperwork yourself rather than taking anyone’s word for it.
This case is one of six. The full picture — every defendant, the legal theory, the FDA backdrop, and the September 24 appellate argument over whether retatrutide is a biologic — is in our live tracker of the Lilly retatrutide lawsuits, which we update as filings land.
Federal dockets via CourtListener/RECAP: Legendary Peptides · Lone Star Peptide · Texas Peptides · Astra LLC · Striker Pharmacy · Aesthetic Envy. Company statement: Eli Lilly, Aug 12 2026. Legal analysis: Frier Levitt. Reporting: BioPharma Dive · CBS News · NPR · FiercePharma. FDA: Concerns with unapproved GLP-1 drugs.
Court records reviewed September 1, 2026. Every characterisation of Eli Lilly’s case is an allegation contained in its complaints; none of the defendants has been found liable, and as of this update none has filed a public denial. Peptides Uncaged is not a party to any of these actions and has no relationship with any defendant. This article is journalism, not legal advice — if a lawsuit affects you, talk to a lawyer. For research use only; nothing here is medical advice.